Immunotherapy: The Need for Critical Studies
Authors: Richard S. Bornstein, J. W. Yarbro, Richmond T. Prehn
Journal: Annals of Internal Medicine (1972)

Editorials1 March 1972Immunotherapy: The Need for Critical StudiesRICHARD S. BORNSTEIN, M.D., J. W. YARBRO, M.D., PH.D., RICHMOND T. PREHN, M.D.RICHARD S. BORNSTEIN, M.D.Search for more papers by this author, J. W. YARBRO, M.D., PH.D.Search for more papers by this author, RICHMOND T. PREHN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-76-3-499 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptExtensive investigation of the immunology of animal neoplasia suggests that host immunity may be a factor of major importance in host resistance to cancer. Although data from humans provide less rigorous evidence, they suggest that man does respond immunologically to tumors. Selected reports (Table 1) indicate that both cellular immunity and circulating antibodies against human cancer have been demonstrated repeatedly by various techniques against a wide spectrum of tumors. Although these are by no means uniform phenomena, it seems probable, especially in malignant melanoma, that the host can mount an immune response against autochthonous neoplastic tissue. Furthermore, a variety of...References1. MORTONEILBERJOSEPH DFW: Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann Surg 172:740-747, 1970 CrossrefMedlineGoogle Scholar2. : Treatment of acute lymphoblastic leukemia. Br Med J 4:189-194, 1971 MedlineGoogle Scholar3. MATHÉ G: Immunotherapy in the treatment of acute lymphoid leukemia. Hosp Pract 6:43-51, 1971 CrossrefGoogle Scholar4. HELLSTRÖMHELLSTRÖMEVANS IKC: Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens. Proc Natl Acad Sci USA 62:362-368, 1969 CrossrefMedlineGoogle Scholar5. PREHNLAPPÉ RM: An immunostimulation theory of tumor development. Transplant Rev. In press Google Scholar6. PREHN R: The immune reaction as a stimulator of tumor growth. Science. In press Google Scholar7. MASTRANGELOBORNSTEINSULIT MRH: Immunotherapy of malignant melanoma. In preparation Google Scholar8. SULITCHEEMASTRANGELO HDM: In vitro assays of cellular and humoral immunity during a clinical trial of immunotherapy in human melanoma. In preparation Google Scholar9. FASSHERBERMANNZIEGLER LRJ: Cutaneous hypersensitivity reactions to autologous extracts of malignant melanoma cells. Lancet 1:116-118, 1970 CrossrefMedlineGoogle Scholar10. LEWISIKONOPISOVNAIRN MRR: Tumor specific antibodies in human malignant melanoma and their relationship to the extent of disease. Br Med J 3:547-552, 1969 CrossrefMedlineGoogle Scholar11. JEHNNATHANSONSCHWARTZ ULR: In vitro lymphocyte stimulation by a soluble antigen from malignant melanoma. N Engl J Med 283:329-333, 1970 CrossrefMedlineGoogle Scholar12. HELLSTRÖMHELLSTRÖM KI: Cellular immunity against tumor antigens. Adv Cancer Res 12:167-223, 1969 CrossrefMedlineGoogle Scholar13. FASSHERBERMANZIEGLER LRJ: Evaluation of the effect of remission plasma on untreated patients with Burkitt's lymphoma. J Natl Cancer Inst 44:145-149, 1970 MedlineGoogle Scholar14. OLDBOYSEOETTGEN LEH: Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proc Natl Acad Sci USA 56:1699-1704, 1966 CrossrefMedlineGoogle Scholar15. HELLSTRÖMHELLSTRÖMPIERCE IKG: Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci USA 60:1231-1238, 1968 CrossrefMedlineGoogle Scholar16. STJERNSWÄRDJOHANSSONSVEDMYR JBE: Indication of tumor specific cell-bound immunological reactivity and depressed general reactivity in a pair of twins. Clin Exp Immunol 6:429-434, 1970 MedlineGoogle Scholar17. MOOREGERNER GR: Cancer immunity—hypothesis and clinical trial of lymphocytotherapy for malignant disease. Ann Surg 172:733-739, 1970 CrossrefMedlineGoogle Scholar18. HUMPHREYJEWELLMURRAY GWD: Immunotherapy for the patient with cancer. Ann Surg 173:47-54, 1971 CrossrefMedlineGoogle Scholar19. CURTIS J: Adoptive immunotherapy in the treatment of advanced malignant melanoma (abstract). Proc Am Assoc Cancer Res 12:52, 1971 Google Scholar20. IKONOPISOVLEWISHUNTER-CRAIG RMI: Autoimmunization with irradiated tumor cells in human malignant melanoma. Br Med J 2:752-754, 1970 CrossrefMedlineGoogle Scholar21. KREMENTZSAMUELSWALLACE EMJ: Clinical experience in immunotherapy of cancer. Surg Gynecol Obstet 133:209-217, 1971 MedlineGoogle Scholar22. MORTONEILBERMALMGREN DFR: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68:158-164, 1970 MedlineGoogle Scholar23. NATHANSON L: Experience with BCG in malignant melanoma (abstract). Proc Am Assoc Cancer Res 12:99, 1971 Google Scholar24. HUGHESKEARNEYTULLEY LRM: A study in clinical cancer immunotherapy. Cancer 26:269-278, 1970 CrossrefMedlineGoogle Scholar25. CZAJKOWSKIROSENBLATTWOLF NMP: A new method of active immunization to autologous human tumor tissue. Lancet 2:905-909, 1967 CrossrefMedlineGoogle Scholar26. BRANDESGALDONWILTSHAW LDE: New approach to immunotherapy of melanoma. Lancet 2:293-295, 1971 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: RICHARD S. BORNSTEIN, M.D.; J. W. YARBRO, M.D., PH.D.; RICHMOND T. PREHN, M.D.Affiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byImmunotherapy of cancer with lymphokines and lymphokine-activated killer cellsThe use of oral BCG in the treatment of metastatic malignant melanomaAutoimmune Diseases of the Skin and Skin Disorders with Diverse Immuno-Pathological AbnormalitiesBCG and Cancer 1 March 1972Volume 76, Issue 3Page: 499-501KeywordsAntibodiesCancer immunotherapyImmune responseImmunityImmunologyMelanoma ePublished: 1 December 2008 Issue Published: 1 March 1972 PDF downloadLoading ...